ACADIA PHARMACEUTICALS INC (ACAD)
US0042251084 - Common Stock
We assign a fundamental rating of 4 out of 10 to ACAD. ACAD was compared to 588 industry peers in the Biotechnology industry. While ACAD seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ACAD is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ACAD had negative earnings in the past year.
ACAD had a positive operating cash flow in the past year.
ACAD had negative earnings in each of the past 5 years.
ACAD had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ACAD's Return On Assets of -8.19% is amongst the best of the industry. ACAD outperforms 90.41% of its industry peers.
ACAD has a better Return On Equity (-14.20%) than 90.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.19% | ||
| ROE | -14.2% | ||
| ROIC | N/A |
ROA(3y)-22.97%
ROA(5y)-26.99%
ROE(3y)-33.06%
ROE(5y)-35.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ACAD (94.27%) is better than 96.06% of its industry peers.
ACAD's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ACAD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.38%
GM growth 5Y0.53%
2. Health
2.1 Basic Checks
ACAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACAD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ACAD has been increased compared to 5 years ago.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 1.90 indicates that ACAD is not a great score, but indicates only limited risk for bankruptcy at the moment.
ACAD has a better Altman-Z score (1.90) than 71.40% of its industry peers.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.9 |
ROIC/WACCN/A
WACC9.26%
2.3 Liquidity
A Current Ratio of 2.42 indicates that ACAD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.42, ACAD is doing worse than 73.97% of the companies in the same industry.
A Quick Ratio of 2.28 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has a Quick ratio of 2.28. This is in the lower half of the industry: ACAD underperforms 73.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.42 | ||
| Quick Ratio | 2.28 |
3. Growth
3.1 Past
ACAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.82%, which is quite impressive.
Looking at the last year, ACAD shows a very strong growth in Revenue. The Revenue has grown by 40.43%.
Measured over the past years, ACAD shows a very strong growth in Revenue. The Revenue has been growing by 26.55% on average per year.
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q207.69%
Revenue 1Y (TTM)40.43%
Revenue growth 3Y18.03%
Revenue growth 5Y26.55%
Revenue growth Q2Q69.26%
3.2 Future
The Earnings Per Share is expected to grow by 54.96% on average over the next years. This is a very strong growth
Based on estimates for the next years, ACAD will show a quite strong growth in Revenue. The Revenue will grow by 19.46% on average per year.
EPS Next Y278.73%
EPS Next 2Y133.91%
EPS Next 3Y90.7%
EPS Next 5Y54.96%
Revenue Next Year34.47%
Revenue Next 2Y23.34%
Revenue Next 3Y20.14%
Revenue Next 5Y19.46%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ACAD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 24.65 indicates a rather expensive valuation of ACAD.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaply inside the industry as 95.72% of the companies are valued more expensively.
ACAD's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.60.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.65 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ACAD's earnings are expected to grow with 90.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y133.91%
EPS Next 3Y90.7%
5. Dividend
5.1 Amount
ACAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACADIA PHARMACEUTICALS INC
NASDAQ:ACAD (4/23/2024, 7:00:00 PM)
After market: 16.74 0 (0%)16.74
-0.25 (-1.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.76B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.65 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.19% | ||
| ROE | -14.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.27% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.97
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.42 | ||
| Quick Ratio | 2.28 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y278.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)40.43%
Revenue growth 3Y18.03%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y